New study from Harvard finds heightened risk of HHV-6 PALE for UCBT patients.
HHV-6 reactivation tied to increased mortality and acute GVHD in HSCT
HHV-6 detection associated with increasingly poor outcome for stem cell transplant patients.
Epilepsy Following HHV-6 Limbic Encephalitis in Pediatric Transplant Patients
A group from the Royal Children’s Hospital in Melbourne, Australia has reported the development of epilepsy after HHV-6 posttransplant limbic encephalitis (PALE) among children receiving stem cell transplantation with cord blood (CBT).
International group of HHV-6 investigators review inherited or “chromosomally integrated” HHV-6 (ciHHV-6)
An international group of HHV-6 experts, investigators and clinicians have published a comprehensive review of chromosomally integrated HHV-6 (ciHHV-6). The article, entitled “Chromosomally Integrated human herpesvirus-6: questions and answers,” is written in response to the widespread confusion in the medical community on how to test or diagnose the condition, as well as how to treat a patient with ciHHV-6 who may or may not have symptoms consistent with HHV-6 reactivation.
Group further characterizes HHV-6 CD4+ T cell response
In a recent publication, investigators from the University of Massachusetts reported the first fine characterization of the CD4+ T cell response to HHV-6.
HHV-6 Reactivation linked to complications in Allogenic Stem Cell Transplantation
Researchers have tied HHV-6 Reactivation to GVHD, seizures, pneumonia, and encephalitis in Allo-SCT patients.
HHV-6 in the liver associated with decreased graft survival
Researchers from the University of Hannover have found a significant association between HHV-6 and decreased graft survival in liver transplant patients.
Case of fatal HHV-6 chronic myocarditis reported in an immunocompetent adult
A group of physicians from the University Hospital in Reims, France, have reported a case of fatal HHV-6 myocarditis in an immunocompetent patient previously thought to be negative for HHV-6 infection.
Two year MS study shows that relapse correlates with HHV-6A reactivation
A new study shows that multiple sclerosis patients with HHV-6 have higher risk of relapse and poor response to IFN-beta treatment.
HHV-6A can travel through the nose to the brain
The trigger for neurological disease in a subset of patients with MS?
Clinical Significance of Pre-Transplant Chromosomally-Integrated HHV-6 in Liver Transplant Recipients
The reactivation of HHV-6 in transplant recipients has long been known to induce clinical complications and poor outcomes following transplantation. However, the clinical relevance of transplant patients with ciHHV-6…
HHV-6 implicated as oncogenic agent in subset of Hodgkin’s Lymphoma
Lacroix et al have published new research revealing the presence of HHV-6B in the Reed Sternberg cells of patients with nodular sclerosis Hodgkin’s lymphoma…
HHV-6 status determines effectiveness of interferon treatment in Multiple Sclerosis
The administration of immune agents to patients (known as Interferon-Beta-1b, or IFN-beta, therapy) has been widely used in the treatment and maintenance of multiple sclerosis (MS). Additionally, it is known that the risk of MS exacerbation is much higher in patients with active HHV-6 infection than in patients with a latent infection of the virus (Lafuente 2006, 2007; Chapenko 2003). …
7th International Conference on HHV-6 & HHV-7 held February 27-March 2, 2011
Over 120 researchers and clinicians from 18 countries gathered in Reston, Virginia. Work was presented on the most recent implications and findings of HHV-6 in a broad spectrum of research and clinical settings.
HHV-6 uses novel form of latency
HHV-6 integrates into the chromosome during latency and reactivates in response to chemical stimulation.